Guiding the attack: CXCR3 leads CAR T cells to pediatric brain tumors

CAR T cell therapies targeting B7-H3 (CD276), a marker expressed on DIPG tumors, have been tested in early phase clinical trials and demonstrated feasibility and tolerability. [...] However, many CAR T cells may struggle to travel into the tumor and exert their cancer-killing effects.

Read more: https://www.fredhutch.org/en/news/spotlight/2026/01/ccsg-song-natcomm.html